Cargando…

Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

BACKGROUND: Schizophrenia is a severe form of mental illness which is associated with significant and long-lasting health, social and financial burdens. The aim of this project is to assess the efficiency of the antipsychotics used in Spain in reducing schizophrenia relapses under the Spanish Health...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Ruiz, Antonio J, Pérez-Costillas, Lucía, Montesinos, Ana C, Alcalde, Javier, Oyagüez, Itziar, Casado, Miguel A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402933/ https://www.ncbi.nlm.nih.gov/pubmed/22828390 http://dx.doi.org/10.1186/2191-1991-2-8

Ejemplares similares

Preemptive TPMT Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases
por: Valdez-Acosta, Sarahí, et al.
Publicado: (2023)

Use of Floseal(®), a human gelatine-thrombin matrix sealant, in surgery: a systematic review
por: Echave, María, et al.
Publicado: (2014)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia
por: Marcus, Steven C., et al.
Publicado: (2008)

Use of Conventional Antipsychotics and the Cost of Treating Schizophrenia
por: Lyu, Ramon R., et al.
Publicado: (2001)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia
por: Morken, Gunnar, et al.
Publicado: (2008)

Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs
por: Homar, Francesc, et al.
Publicado: (2012)

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
por: Mareque, Maria, et al.
Publicado: (2021)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Cost Analysis of FreeStyle Libre(®) 2 System in Type 2 Diabetes Mellitus Population
por: Oyagüez, Itziar, et al.
Publicado: (2021)

Correction to: Cost Analysis of FreeStyle Libre(®) 2 System in Type 2 Diabetes Mellitus Population
por: Oyagüez, Itziar, et al.
Publicado: (2021)

Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia
por: Wei, Yue, et al.
Publicado: (2022)

Cost analysis of the flash monitoring system (FreeStyle Libre 2) in adults with type 1 diabetes mellitus
por: Oyagüez, Itziar, et al.
Publicado: (2020)

Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
por: Alsina, Laia, et al.
Publicado: (2021)

Correction to: Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
Publicado: (2022)

Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain
por: Rodríguez González-Moro, Jose Miguel, et al.
Publicado: (2015)

Estimating cost-offsets of new medications: Use of new antipsychotics and mental health costs for schizophrenia
por: O'Malley, A James, et al.
Publicado: (2011)

Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone(®)) in Spain
por: Martinez-Raga, Jose, et al.
Publicado: (2012)

Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort Study
por: Ahmadkhaniha, Hamid-Reza, et al.
Publicado: (2014)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
por: Navarro, F., et al.
Publicado: (2020)

Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis
por: Gros, Blanca, et al.
Publicado: (2015)

Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand
por: Boonlue, Tuanthon, et al.
Publicado: (2016)

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil
por: Barbosa, Wallace Breno, et al.
Publicado: (2018)

Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia
por: Panish, Jessica, et al.
Publicado: (2013)

F121. DOES RELAPSE CONTRIBUTE TO TREATMENT RESISTANCE? ANTIPSYCHOTIC RESPONSE IN FIRST- VS. SECOND-EPISODE SCHIZOPHRENIA
por: Takeuchi, Hiroyoshi, et al.
Publicado: (2018)

Comparison of cost-effectiveness of long-acting depot injection antipsychotics and oral antipsychotics in patients with schizophrenia in a rural community in South India
por: Raghavan, Vijaya, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
por: Capel, Margarita, et al.
Publicado: (2019)

Antipsychotic agents: efficacy and safety in schizophrenia
por: de Araújo, Arão Nogueira, et al.
Publicado: (2012)

Comparative effectiveness of antipsychotic drugs in schizophrenia
por: Stroup, T. Scott, et al.
Publicado: (2000)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia
por: Wu, Haishan, et al.
Publicado: (2013)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

Choosing an Optimal Antipsychotic Dose for Relapse Prevention
por: Davis, John M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cbg73m9h86krr9kff6fjosp37f